Daniel Gerlach
11PUBLICATIONS
90CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (11)
Sort by Publication Date:
|Dec 23, 2024
Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.Antonio Tedeschi, Fiorella Schischlik, Francesca Rocchetti
|Oct 22, 2024
SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.Brianna R Daley, Nancy E Sealover, Bridget A Finniff
|Sep 11, 2024
Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules.Andreas Gollner, Dorothea Rudolph, Ulrike Weyer-Czernilofsky
|Sep 09, 2024
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.Birgit Wilding, Lydia Woelflingseder, Anke Baum
|Aug 05, 2024
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.Venu Thatikonda, Hengyu Lyu, Sabine Jurado
|Jul 26, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.Birgit Wilding, Dirk Scharn, Dietrich Böse
Pageof 2
Frequent Collaborators
6 joint publications
Norbert Kraut
4 joint publications
Marco H Hofmann
2 joint publications
Johannes Zuber
2 joint publications
Flavio Solca
2 joint publications
Gerd Bader
2 joint publications
Ralph A Neumüller
2 joint publications
Birgit Wilding
2 joint publications
Darryl B McConnell
2 joint publications
Mark Petronczki
2 joint publications
Timothy P Heffernan
